APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Stromal Tumor (GIST) Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Gastrointestinal Stromal Tumor (GIST) Drug Industry Research Report 2026

22 December 2025130 pages

Choose your research edition.

Industry ResearchGastrointestinal Stromal Tumor (GIST) Drug Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Stromal Tumor (GIST) Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Stromal Tumor (GIST) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Stromal Tumor (GIST) Drug Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Stromal Tumor (GIST) Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Gastrointestinal Stromal Tumor (GIST) Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Gastrointestinal Stromal Tumor (GIST) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Gastrointestinal Stromal Tumor (GIST) Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Gastrointestinal Stromal Tumor (GIST) Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug include Novartis AG, Jiangsu Hengrui Medicine Co., Ltd., Omeros Corporation, Nerviano Medical Sciences S.r.l., Natco Pharma Limited, Kolltan Pharmaceuticals, Inc., Immunicum AB, Horizon Pharma Plc and F. Hoffmann-La Roche Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Gastrointestinal Stromal Tumor (GIST) Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Gastrointestinal Stromal Tumor (GIST) Drug Market by Company

Novartis AG

Jiangsu Hengrui Medicine Co., Ltd.

Omeros Corporation

Nerviano Medical Sciences S.r.l.

Natco Pharma Limited

Kolltan Pharmaceuticals, Inc.

Immunicum AB

Horizon Pharma Plc

F. Hoffmann-La Roche Ltd.

Deciphera Pharmaceuticals, LLC

Chipscreen Biosciences Ltd

Calithera Biosciences, Inc.

Boston Biomedical, Inc.

Blueprint Medicines Corporation

Astex Pharmaceuticals, Inc.

Array BioPharma Inc.

Arog Pharmaceuticals, Inc.

Ariad Pharmaceuticals, Inc.

Gastrointestinal Stromal Tumor (GIST) Drug Segment by Type

Amcasertib

Anagrelide hydrochloride CR

APG-1351

Binimetinib

Others

Gastrointestinal Stromal Tumor (GIST) Drug Segment by Application

Clinic

Hospital

Others

Gastrointestinal Stromal Tumor (GIST) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Stromal Tumor (GIST) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Stromal Tumor (GIST) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Stromal Tumor (GIST) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumor (GIST) Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Gastrointestinal Stromal Tumor (GIST) Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Gastrointestinal Stromal Tumor (GIST) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Gastrointestinal Stromal Tumor (GIST) Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue of Manufacturers (2021-2026) Table 9. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Gastrointestinal Stromal Tumor (GIST) Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Gastrointestinal Stromal Tumor (GIST) Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug, Product Type & Application Table 14. Global Gastrointestinal Stromal Tumor (GIST) Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Gastrointestinal Stromal Tumor (GIST) Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Novartis AG Company Information Table 19. Novartis AG Business Overview Table 20. Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 22. Novartis AG Recent Developments Table 23. Jiangsu Hengrui Medicine Co., Ltd. Company Information Table 24. Jiangsu Hengrui Medicine Co., Ltd. Business Overview Table 25. Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 27. Jiangsu Hengrui Medicine Co., Ltd. Recent Developments Table 28. Omeros Corporation Company Information Table 29. Omeros Corporation Business Overview Table 30. Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 32. Omeros Corporation Recent Developments Table 33. Nerviano Medical Sciences S.r.l. Company Information Table 34. Nerviano Medical Sciences S.r.l. Business Overview Table 35. Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 37. Nerviano Medical Sciences S.r.l. Recent Developments Table 38. Natco Pharma Limited Company Information Table 39. Natco Pharma Limited Business Overview Table 40. Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 42. Natco Pharma Limited Recent Developments Table 43. Kolltan Pharmaceuticals, Inc. Company Information Table 44. Kolltan Pharmaceuticals, Inc. Business Overview Table 45. Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 47. Kolltan Pharmaceuticals, Inc. Recent Developments Table 48. Immunicum AB Company Information Table 49. Immunicum AB Business Overview Table 50. Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 52. Immunicum AB Recent Developments Table 53. Horizon Pharma Plc Company Information Table 54. Horizon Pharma Plc Business Overview Table 55. Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 57. Horizon Pharma Plc Recent Developments Table 58. F. Hoffmann-La Roche Ltd. Company Information Table 59. F. Hoffmann-La Roche Ltd. Business Overview Table 60. F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 62. F. Hoffmann-La Roche Ltd. Recent Developments Table 63. Deciphera Pharmaceuticals, LLC Company Information Table 64. Deciphera Pharmaceuticals, LLC Business Overview Table 65. Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 67. Deciphera Pharmaceuticals, LLC Recent Developments Table 68. Chipscreen Biosciences Ltd Company Information Table 69. Chipscreen Biosciences Ltd Business Overview Table 70. Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 72. Chipscreen Biosciences Ltd Recent Developments Table 73. Calithera Biosciences, Inc. Company Information Table 74. Calithera Biosciences, Inc. Business Overview Table 75. Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 77. Calithera Biosciences, Inc. Recent Developments Table 78. Boston Biomedical, Inc. Company Information Table 79. Boston Biomedical, Inc. Business Overview Table 80. Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 82. Boston Biomedical, Inc. Recent Developments Table 83. Blueprint Medicines Corporation Company Information Table 84. Blueprint Medicines Corporation Business Overview Table 85. Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 87. Blueprint Medicines Corporation Recent Developments Table 88. Astex Pharmaceuticals, Inc. Company Information Table 89. Astex Pharmaceuticals, Inc. Business Overview Table 90. Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 92. Astex Pharmaceuticals, Inc. Recent Developments Table 93. Array BioPharma Inc. Company Information Table 94. Array BioPharma Inc. Business Overview Table 95. Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 97. Array BioPharma Inc. Recent Developments Table 98. Arog Pharmaceuticals, Inc. Company Information Table 99. Arog Pharmaceuticals, Inc. Business Overview Table 100. Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 102. Arog Pharmaceuticals, Inc. Recent Developments Table 103. Ariad Pharmaceuticals, Inc. Company Information Table 104. Ariad Pharmaceuticals, Inc. Business Overview Table 105. Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio Table 107. Ariad Pharmaceuticals, Inc. Recent Developments Table 108. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region (2021-2026) & (k units) Table 110. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region (2021-2026) Table 111. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region (2027-2032) & (k units) Table 112. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Region (2027-2032) Table 113. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Region (2021-2026) Table 115. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Region (2027-2032) Table 117. North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2026) & (k units) Table 119. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2027-2032) & (k units) Table 120. North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2026) & (k units) Table 124. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2027-2032) & (k units) Table 125. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2026) & (k units) Table 129. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2027-2032) & (k units) Table 130. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2026) & (k units) Table 134. South America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2027-2032) & (k units) Table 135. South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2026) & (k units) Table 139. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2027-2032) & (k units) Table 140. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2021-2026) & (k units) Table 143. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2027-2032) & (k units) Table 144. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2021-2026) Table 145. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2027-2032) Table 146. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2021-2026) Table 149. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2027-2032) Table 150. Global Gastrointestinal Stromal Tumor (GIST) Drug Price by Type (2021-2026) & (US$/unit) Table 151. Global Gastrointestinal Stromal Tumor (GIST) Drug Price by Type (2027-2032) & (US$/unit) Table 152. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2021-2026) & (k units) Table 153. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2027-2032) & (k units) Table 154. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2021-2026) Table 155. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2027-2032) Table 156. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application (2021-2026) Table 159. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application (2027-2032) Table 160. Global Gastrointestinal Stromal Tumor (GIST) Drug Price by Application (2021-2026) & (US$/unit) Table 161. Global Gastrointestinal Stromal Tumor (GIST) Drug Price by Application (2027-2032) & (US$/unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Gastrointestinal Stromal Tumor (GIST) Drug Distributors List Table 165. Gastrointestinal Stromal Tumor (GIST) Drug Customers List Table 166. Gastrointestinal Stromal Tumor (GIST) Drug Industry Trends Table 167. Gastrointestinal Stromal Tumor (GIST) Drug Industry Drivers Table 168. Gastrointestinal Stromal Tumor (GIST) Drug Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Gastrointestinal Stromal Tumor (GIST) Drug Product Image Figure 5. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales (2021-2032) & (k units) Figure 8. Global Gastrointestinal Stromal Tumor (GIST) Drug Average Price (US$/unit) & (2021-2032) Figure 9. Amcasertib Product Image Figure 10. Anagrelide hydrochloride CR Product Image Figure 11. APG-1351 Product Image Figure 12. Binimetinib Product Image Figure 13. Others Product Image Figure 14. Clinic Product Image Figure 15. Hospital Product Image Figure 16. Others Product Image Figure 17. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Gastrointestinal Stromal Tumor (GIST) Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region in 2025 Figure 23. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region in 2025 Figure 24. North America Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country in 2025 Figure 25. North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2021-2032) Figure 26. North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country in 2025 Figure 31. Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2021-2032) Figure 32. Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2021-2032) Figure 33. Germany Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country in 2025 Figure 44. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2021-2032) Figure 46. China Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country in 2025 Figure 55. South America Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2021-2032) Figure 56. South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2021-2032) Figure 57. Brazil Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country in 2025 Figure 61. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Country (2021-2032) Figure 63. Egypt Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Gastrointestinal Stromal Tumor (GIST) Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2021-2032) Figure 69. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2021-2032) Figure 70. Global Gastrointestinal Stromal Tumor (GIST) Drug Price (US$/unit) by Type (2021-2032) Figure 71. Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2021-2032) Figure 72. Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application (2021-2032) Figure 73. Global Gastrointestinal Stromal Tumor (GIST) Drug Price (US$/unit) by Application (2021-2032) Figure 74. Gastrointestinal Stromal Tumor (GIST) Drug Value Chain Figure 75. Gastrointestinal Stromal Tumor (GIST) Drug Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Gastrointestinal Stromal Tumor (GIST) Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Amcasertib
  • Anagrelide hydrochloride CR
  • APG-1351
  • Binimetinib
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Novartis AG
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Omeros Corporation
  • Nerviano Medical Sciences S.r.l.
  • Natco Pharma Limited
  • Kolltan Pharmaceuticals, Inc.
  • Immunicum AB
  • Horizon Pharma Plc
  • F. Hoffmann-La Roche Ltd.
  • Deciphera Pharmaceuticals, LLC
  • Chipscreen Biosciences Ltd
  • Calithera Biosciences, Inc.
  • Boston Biomedical, Inc.
  • Blueprint Medicines Corporation
  • Astex Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Arog Pharmaceuticals, Inc.
  • Ariad Pharmaceuticals, Inc.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size (2021-2032)
  4. 2.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales (2021-2032)
  5. 2.2.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Average Price (2021-2032)
  6. 2.3 Gastrointestinal Stromal Tumor (GIST) Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Amcasertib
  9. 2.3.3 Anagrelide hydrochloride CR
  10. 2.3.4 APG-1351
  11. 2.3.5 Binimetinib
  12. 2.3.6 Others
  13. 2.4 Gastrointestinal Stromal Tumor (GIST) Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Clinic
  16. 2.4.3 Hospital
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Gastrointestinal Stromal Tumor (GIST) Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug, Established Date
  9. 3.9 Global Gastrointestinal Stromal Tumor (GIST) Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Novartis AG
  2. 4.1.1 Novartis AG Company Information
  3. 4.1.2 Novartis AG Business Overview
  4. 4.1.3 Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  6. 4.1.5 Novartis AG Recent Developments
  7. 4.2 Jiangsu Hengrui Medicine Co., Ltd.
  8. 4.2.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
  9. 4.2.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
  10. 4.2.3 Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  12. 4.2.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
  13. 4.3 Omeros Corporation
  14. 4.3.1 Omeros Corporation Company Information
  15. 4.3.2 Omeros Corporation Business Overview
  16. 4.3.3 Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  18. 4.3.5 Omeros Corporation Recent Developments
  19. 4.4 Nerviano Medical Sciences S.r.l.
  20. 4.4.1 Nerviano Medical Sciences S.r.l. Company Information
  21. 4.4.2 Nerviano Medical Sciences S.r.l. Business Overview
  22. 4.4.3 Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  24. 4.4.5 Nerviano Medical Sciences S.r.l. Recent Developments
  25. 4.5 Natco Pharma Limited
  26. 4.5.1 Natco Pharma Limited Company Information
  27. 4.5.2 Natco Pharma Limited Business Overview
  28. 4.5.3 Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  30. 4.5.5 Natco Pharma Limited Recent Developments
  31. 4.6 Kolltan Pharmaceuticals, Inc.
  32. 4.6.1 Kolltan Pharmaceuticals, Inc. Company Information
  33. 4.6.2 Kolltan Pharmaceuticals, Inc. Business Overview
  34. 4.6.3 Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  36. 4.6.5 Kolltan Pharmaceuticals, Inc. Recent Developments
  37. 4.7 Immunicum AB
  38. 4.7.1 Immunicum AB Company Information
  39. 4.7.2 Immunicum AB Business Overview
  40. 4.7.3 Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  42. 4.7.5 Immunicum AB Recent Developments
  43. 4.8 Horizon Pharma Plc
  44. 4.8.1 Horizon Pharma Plc Company Information
  45. 4.8.2 Horizon Pharma Plc Business Overview
  46. 4.8.3 Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  48. 4.8.5 Horizon Pharma Plc Recent Developments
  49. 4.9 F. Hoffmann-La Roche Ltd.
  50. 4.9.1 F. Hoffmann-La Roche Ltd. Company Information
  51. 4.9.2 F. Hoffmann-La Roche Ltd. Business Overview
  52. 4.9.3 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  54. 4.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
  55. 4.10 Deciphera Pharmaceuticals, LLC
  56. 4.10.1 Deciphera Pharmaceuticals, LLC Company Information
  57. 4.10.2 Deciphera Pharmaceuticals, LLC Business Overview
  58. 4.10.3 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  60. 4.10.5 Deciphera Pharmaceuticals, LLC Recent Developments
  61. 4.11 Chipscreen Biosciences Ltd
  62. 4.11.1 Chipscreen Biosciences Ltd Company Information
  63. 4.11.2 Chipscreen Biosciences Ltd Business Overview
  64. 4.11.3 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  66. 4.11.5 Chipscreen Biosciences Ltd Recent Developments
  67. 4.12 Calithera Biosciences, Inc.
  68. 4.12.1 Calithera Biosciences, Inc. Company Information
  69. 4.12.2 Calithera Biosciences, Inc. Business Overview
  70. 4.12.3 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  72. 4.12.5 Calithera Biosciences, Inc. Recent Developments
  73. 4.13 Boston Biomedical, Inc.
  74. 4.13.1 Boston Biomedical, Inc. Company Information
  75. 4.13.2 Boston Biomedical, Inc. Business Overview
  76. 4.13.3 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  78. 4.13.5 Boston Biomedical, Inc. Recent Developments
  79. 4.14 Blueprint Medicines Corporation
  80. 4.14.1 Blueprint Medicines Corporation Company Information
  81. 4.14.2 Blueprint Medicines Corporation Business Overview
  82. 4.14.3 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  84. 4.14.5 Blueprint Medicines Corporation Recent Developments
  85. 4.15 Astex Pharmaceuticals, Inc.
  86. 4.15.1 Astex Pharmaceuticals, Inc. Company Information
  87. 4.15.2 Astex Pharmaceuticals, Inc. Business Overview
  88. 4.15.3 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  90. 4.15.5 Astex Pharmaceuticals, Inc. Recent Developments
  91. 4.16 Array BioPharma Inc.
  92. 4.16.1 Array BioPharma Inc. Company Information
  93. 4.16.2 Array BioPharma Inc. Business Overview
  94. 4.16.3 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  96. 4.16.5 Array BioPharma Inc. Recent Developments
  97. 4.17 Arog Pharmaceuticals, Inc.
  98. 4.17.1 Arog Pharmaceuticals, Inc. Company Information
  99. 4.17.2 Arog Pharmaceuticals, Inc. Business Overview
  100. 4.17.3 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  102. 4.17.5 Arog Pharmaceuticals, Inc. Recent Developments
  103. 4.18 Ariad Pharmaceuticals, Inc.
  104. 4.18.1 Ariad Pharmaceuticals, Inc. Company Information
  105. 4.18.2 Ariad Pharmaceuticals, Inc. Business Overview
  106. 4.18.3 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
  108. 4.18.5 Ariad Pharmaceuticals, Inc. Recent Developments
5 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Scenario by Region
  1. 5.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region: 2027-2032
  5. 5.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region: 2027-2032
  8. 5.4 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
  9. 5.4.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
  41. 5.7.1 South America Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Gastrointestinal Stromal Tumor (GIST) Drug Value Chain Analysis
  2. 8.1.1 Gastrointestinal Stromal Tumor (GIST) Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Gastrointestinal Stromal Tumor (GIST) Drug Production Mode & Process
  5. 8.2 Gastrointestinal Stromal Tumor (GIST) Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Gastrointestinal Stromal Tumor (GIST) Drug Distributors
  8. 8.2.3 Gastrointestinal Stromal Tumor (GIST) Drug Customers
9 Global Gastrointestinal Stromal Tumor (GIST) Drug Analyzing Market Dynamics
  1. 9.1 Gastrointestinal Stromal Tumor (GIST) Drug Industry Trends
  2. 9.2 Gastrointestinal Stromal Tumor (GIST) Drug Industry Drivers
  3. 9.3 Gastrointestinal Stromal Tumor (GIST) Drug Industry Opportunities and Challenges
  4. 9.4 Gastrointestinal Stromal Tumor (GIST) Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst